The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
Patients who do not achieve sustained virological response to telaprevir/peginterferon (PEG‐IFN)/ribavirin need to be identified. Predictive factors of virological response to the triple therapy in non‐responders to previous PEG‐IFN/ribavirin therapy are not clear. The aims of this study were to determine the predictive factors of virological response to a 24‐week regimen of triple therapy in 15 non‐responders...
Substitution of amino acid (aa) 70 and 91 in the core region of hepatitis C virus (HCV) genotype 1b can predict the response to pegylated interferon (PEG‐IFN)/ribavirin combination therapy, but its impact on triple therapy of telaprevir/PEG‐IFN/ribavirin is not clear. The aims of this study were to investigate the rate of HCV RNA loss following 12‐week triple therapy, and determine the effect of aa...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.